🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I spoke to MM+M about the current real-world data landscape, and how Verily is working on solutions to generate high-quality and reliable RWD.

Congrats to Vindell Washington on this honor! Vindell has committed his career to advancing health equity. We’re lucky to have him on the Verily team!

Yesterday we launched Viewpoint Workbench to help researchers unify multimodal data sets and collaborate securely. We’re excited to welcome our first partners to the platform, Helix, michaeljfox.org and Target ALS!

Thrilled to see the expansion of Verily's Wastewater work through this new contract with CDC.

Terrific to see this latest milestone from our work with covujese, congrats to the teams!

Cell and gene therapies will require new evidence generation approaches to meet regulatory requirements for long term follow-up. This Pink Sheet, Citeline Regulatory article by Kate Rawson Powell covers my remarks at Friends of Cancer Research’s meeting on how we can build what’s needed. pink.citeline.com/PS148912/CellG…

Expanding participation in clinical trials is key to generating the evidence needed to advance precision health. ARPA-H's launch of ARPANET-H is an exciting milestone in making clinical trials more accessible to all.

Yesterday we announced an exciting new partnership with Georgiamune Inc. to advance cancer treatment. This collaboration will combine our expertise in clinical research with Georgiamune’s innovative approach to immunotherapy development. verily.com/perspectives/g…

Can't wait for @CNSsummit next week - I'll join Meg Tirrell for a fireside chat on the current and future state of clinical research, and how biopharma can advance new approaches to benefit patients. Amir Kalali, MD 🌐 @gil_bashe #CNSSummit2023

I look forward to speaking at the #MIHealthSummit tomorrow on what's needed to continue advancing biomedical innovation, with rberke, Dr. Janet Woodcock, Silvia Taylor, and Christopher Austin.

Proud to collaborate with National Academy of Medicine’s Committee on Emerging Science and Technology on three new case studies covering neurotechnology, telehealth, and regenerative medicine - now available here: doi.org/10.31478/20231…

I'm en route to the #PersonalizedMedicine Conference where tomorrow I'll give a keynote, "Unlocking the Future of Precision Health Through Participant-Centric Evidence Generation". Looking forward to it!  personalizedmedicineconference.org/sessions/closi…

This new scorecard will help guide innovation post COVID-19. So pleased to have shared my perspective for the report. Read it here: milkeninstitute.org/report/biomedi…

An important part of the @CancerX initiative is their approach to driving innovation across the entire healthcare system. Excited to see how the project will help transform cancer treatment and prevention, and I’m so glad that Verily has joined the partnership.

I'm honored to be joining a conversation with Ted Love of @IamBiotech and John Crowley of Amicus Therapeutics, during the 2024 Lake Nona Impact Forum in Orlando, FL. We'll be discussing the cutting edge of drug discovery, and what's needed to advance innovation. #LNIF24

It was great to join Jacob Effron on the Vital Signs podcast. We discussed many topics near to my heart, including what's needed to continue advancing evidence generation, and how AI will fit into that story.

We're thrilled to welcome Dr. Amy Abernethy to our BOD! A clinical research pioneer & hematologist-oncologist, her dedication to data-driven healthcare innovation and transformative drug development on behalf of patients align perfectly with our mission. businesswire.com/news/home/2024…

Just back home after #ESMO2024 - it was a pleasure to speak about "Applications of AI in precision oncology" alongside Amy Abernethy and Tom Powles . Content is still on the ESMO - Eur. Oncology website (requires login): esmocongress.esmo.org/esmo/esmo2024/…

Between alarms and sheltering, I learned last night that my postdoc mentor, Professor Atul Butte Atul Butte, has passed away, and he is only 55 years old. This is devastating news 💔. Atul was a giant in so many ways. He was a visionary leader in translational bioinformatics

Atul was a visionary whose infectious enthusiasm will live on and power the generations. We will miss you, Friend.